The Journal of Urology
Volume 174, Issue 1 , Pages 161-164, July 2005

TREATMENT OF CHRONIC BACTERIAL PROSTATITIS WITH LEVOFLOXACIN AND CIPROFLOXACIN LOWERS SERUM PROSTATE SPECIFIC ANTIGEN

  • ANTHONY J. SCHAEFFER

      Affiliations

    • Financial interest and/or other relationship with Ortho-McNeil, Proctor & Gamble, Urologix and Boehringer Ingelheim.
  • ,
  • SHU-CHEN WU

      Affiliations

    • Financial interest and/or other relationship with Ortho-McNeil Pharmaceutical.
  • ,
  • ALAN M. TENNENBERG

      Affiliations

    • Financial interest and/or other relationship with Johnson and Johnson.
  • ,
  • JAMES B. KAHN

      Affiliations

    • Corresponding Author InformationOrtho-McNeil Pharmaceutical, Inc. 1000 Route 202, Room 3162, Raritan, New Jersey 08869-0602 (telephone: 908-704-5262; FAX: 908-218-1286).

From the Northwestern University Medical School (AJS), Chicago, Illinois, and Ortho-McNeil Pharmaceutical, Inc. (S-CW, JBK), Raritan and Tibotec Therapeutics (AMT), Bridgewater, New Jersey

ABSTRACT 

Purpose:

We compared baseline and post-therapy prostate specific antigen (PSA) in patients with chronic bacterial prostatitis who were treated with levofloxacin or ciprofloxacin.

Materials and Methods:

Subset analysis was done using a randomized, multicenter, double-blind, active control trial of 500 mg levofloxacin daily for 28 days vs 500 mg ciprofloxacin twice daily in 28 days in men with chronic bacterial prostatitis.

Results:

Of the 377 men in the intent to treat population, including 197 treated with levofloxacin and 180 treated with ciprofloxacin, 35 on levofloxacin and 37 on ciprofloxacin with baseline PSA greater than 4 ng/ml were included in this analysis. Excluded from analysis were 2 levofloxacin treated patients with extremely high PSA at baseline (62 and 103 ng/ml, respectively). Mean baseline PSA ± SD in the patients analyzed was 8.33 ± 4.46 ng/ml, which decreased to 5.36 ± 3.82 ng/ml after therapy. There was no significant difference in the mean change in PSA between the levofloxacin and ciprofloxacin groups. Approximately 42% of patients with increased baseline PSA had a post-therapy PSA of 4 ng/ml or less. Of patients who were microbiologically evaluable and had normalized PSA after therapy levofloxacin eradicated the pathogen in 90.9% (10 of 11). However, of patients in whom post-therapy PSA remained increased the microbiological eradication rate was 69.2% (9 of 13). Similarly 93.3% of the ciprofloxacin group (14 of 15 patients) with normalized post-therapy PSA experienced microbiological eradication compared with 61.5% (8 of 13) with continued increased PSA after therapy.

Conclusions:

Approximately 20% of patients diagnosed with chronic bacterial prostatitis had increased PSA. A significant decrease in PSA was observed in these patients after treatment with levofloxacin or ciprofloxacin. An association was observed between bacterial persistence and the likelihood that PSA would return to normal.

Key Words::  prostate , prostatitis , ofloxacin , ciprofloxacin , prostate-specific antigen

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Submitted for publication August 12, 2004.

PII: S0022-5347(05)60049-3

doi:10.1097/01.ju.0000162017.24965.2b

The Journal of Urology
Volume 174, Issue 1 , Pages 161-164, July 2005